(MedPage Today) — The first interim safety results from a multicenter, safety surveillance study of Alzheimer’s disease patients treated with lecanemab (Leqembi) in real-world clinical practice were consistent with the known safety profile of…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
